

Richard Musil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2774403/publications.pdf>

Version: 2024-02-01

53
papers

1,723
citations

304368

22
h-index

288905

40
g-index

57
all docs

57
docs citations

57
times ranked

2723
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequential Social Exclusion in a Novel Cyberball Paradigm Leads to Reduced Behavioral Repair and Plasma Oxytocin in Borderline Personality Disorder. <i>Journal of Personality Disorders</i> , 2022, 36, 99-115.	0.8	6
2	Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. <i>Journal of Affective Disorders</i> , 2022, 299, 73-84.	2.0	6
3	Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1331-1341.	1.8	4
4	Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline—Results From a Randomized Controlled Clinical Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 615261.	1.3	10
5	Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110391.	2.5	43
6	Review and Consensus on Pharmacogenomic Testing in Psychiatry. <i>Pharmacopsychiatry</i> , 2021, 54, 5-17.	1.7	96
7	Altered immediate behavioral response to partial social exclusion: A cross-diagnostic study in patients with borderline personality disorder and persistent depressive disorder. <i>Journal of Psychiatric Research</i> , 2021, 144, 177-183.	1.5	3
8	Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 425-431.	1.8	5
9	The vicious circle of social exclusion and psychopathology: a systematic review of experimental ostracism research in psychiatric disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 521-532.	1.8	51
10	Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in Psychiatry (MiP) Study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 597-609.	1.8	20
11	What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 661-671.	1.8	7
12	Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 295-314.	1.0	122
13	Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. <i>Frontiers in Psychiatry</i> , 2019, 10, 458.	1.3	111
14	SU105BRAIN CELL TYPE-SPECIFIC POLYGENIC RISK IN SCHIZOPHRENIA: INFLUENCE ON CLINICAL PHENOTYPES. <i>European Neuropsychopharmacology</i> , 2019, 29, S1322.	0.3	0
15	Promotion of Wellbeing for Children of Parents With Mental Illness: A Model Protocol for Research and Intervention. <i>Frontiers in Psychiatry</i> , 2019, 10, 606.	1.3	20
16	Remission in schizophrenia " What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. <i>Schizophrenia Research</i> , 2019, 209, 185-192.	1.1	5
17	Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. <i>Pharmacopsychiatry</i> , 2019, 52, 180-185.	1.7	0
18	QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 383-390.	1.8	22

#	ARTICLE	IF	CITATIONS
19	Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder. <i>Clinical Neurology and Neurosurgery</i> , 2018, 170, 34-37.	0.6	15
20	Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, .	1.1	34
21	Cathodal tDCS Over Motor Cortex Does Not Improve Tourette Syndrome: Lessons Learned From a Case Series. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 194.	1.0	20
22	Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics. <i>Pharmacogenomics</i> , 2018, 19, 927-930.	0.6	2
23	Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?. <i>Pharmacopsychiatry</i> , 2017, 50, 136-144.	1.7	3
24	Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. <i>Cognitive Neuropsychiatry</i> , 2017, 22, 280-297.	0.7	14
25	Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 303-313.	1.8	8
26	High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib. <i>Frontiers in Psychiatry</i> , 2017, 8, 16.	1.3	33
27	Challenging the understanding of significant improvement and outcome in schizophrenia – the concept of reliable and clinically significant change methods. <i>International Journal of Methods in Psychiatric Research</i> , 2016, 25, 3-11.	1.1	5
28	What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 107-116.	1.8	26
29	Weight gain and antipsychotics: a drug safety review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 73-96.	1.0	155
30	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 51, 190-195.	2.5	10
31	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 567-575.	1.8	38
32	No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 405-412.	1.8	18
33	Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations. <i>CNS Drugs</i> , 2013, 27, 545-572.	2.7	88
34	Genetics of emergent suicidality during antidepressive treatment – Data from a naturalistic study on a large sample of inpatients with a major depressive episode. <i>European Neuropsychopharmacology</i> , 2013, 23, 663-674.	0.3	21
35	Akathisia and Suicidal Ideation in First-Episode Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 694-698.	0.7	29
36	One-year functional outcomes of naturalistically treated patients with schizophrenia. <i>Psychiatry Research</i> , 2012, 198, 378-385.	1.7	34

#	ARTICLE	IF	CITATIONS
37	The CNR1 gene in depression and schizophrenia – Is there an association with early improvement and response?. Psychiatry Research, 2012, 196, 160.	1.7	11
38	Response trajectories in “real-world” naturalistically treated schizophrenia patients. Schizophrenia Research, 2012, 139, 218-224.	1.1	26
39	Functional Outcomes in Schizophrenia: Employment Status as a Metric of Treatment Outcome. Current Psychiatry Reports, 2012, 14, 229-236.	2.1	27
40	Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?. BMC Medicine, 2012, 10, 17.	2.3	13
41	Effectiveness of Quetiapine in Outpatients With Schizophrenia Assessed Under "Real-Life" Conditions. Journal of Clinical Psychopharmacology, 2011, 31, 120-122.	0.7	1
42	Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. Journal of Psychiatric Research, 2011, 45, 234-241.	1.5	55
43	Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients. , 2011, , 93-107.		0
44	Suicidality and Outcome in Schizophrenia Patients. , 2011, , 365-382.		0
45	A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. Psychiatric Genetics, 2010, 20, 35-38.	0.6	39
46	Safety evaluation of zotepine for the treatment of schizophrenia. Expert Opinion on Drug Safety, 2010, 9, 659-666.	1.0	2
47	Outcomes of 1014 naturalistically treated inpatients with major depressive episode. European Neuropsychopharmacology, 2010, 20, 346-355.	0.3	72
48	Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Research, 2010, 121, 118-124.	1.1	227
49	Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trial of treatment with atypical antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 335-344.	1.8	32
50	SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. Journal of Psychiatric Research, 2008, 42, 963-970.	1.5	38
51	Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 402-412.	1.8	40
52	Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 432-437.	1.8	49
53	Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication. European Archives of Psychiatry and Clinical Neuroscience, 0, , .	1.8	4